WO2016138610A1 - Variant de ligand induisant l'apoptose apparenté au facteur de nécrose des tumeurs conjugué à l'albumine, procédé de préparation associé et utilisation associée - Google Patents
Variant de ligand induisant l'apoptose apparenté au facteur de nécrose des tumeurs conjugué à l'albumine, procédé de préparation associé et utilisation associée Download PDFInfo
- Publication number
- WO2016138610A1 WO2016138610A1 PCT/CN2015/073483 CN2015073483W WO2016138610A1 WO 2016138610 A1 WO2016138610 A1 WO 2016138610A1 CN 2015073483 W CN2015073483 W CN 2015073483W WO 2016138610 A1 WO2016138610 A1 WO 2016138610A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- albumin
- necrosis factor
- tumor necrosis
- inducing ligand
- related apoptosis
- Prior art date
Links
- 108010088751 Albumins Proteins 0.000 title claims abstract description 75
- 102000009027 Albumins Human genes 0.000 title claims abstract description 74
- 108700012411 TNFSF10 Proteins 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 239000002773 nucleotide Substances 0.000 claims abstract description 17
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 17
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 13
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 31
- 108091026890 Coding region Proteins 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 229940041181 antineoplastic drug Drugs 0.000 claims description 6
- 238000010353 genetic engineering Methods 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 125000003835 nucleoside group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 30
- 102000008100 Human Serum Albumin Human genes 0.000 description 25
- 108091006905 Human Serum Albumin Proteins 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 description 22
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- 230000000259 anti-tumor effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 9
- 238000002523 gelfiltration Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102000007562 Serum Albumin Human genes 0.000 description 4
- 108010071390 Serum Albumin Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000022534 cell killing Effects 0.000 description 4
- 230000005917 in vivo anti-tumor Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000011503 in vivo imaging Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000037323 metabolic rate Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000830565 Homo sapiens Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 1
- 101000610602 Homo sapiens Tumor necrosis factor receptor superfamily member 10C Proteins 0.000 description 1
- 101000610609 Homo sapiens Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 description 1
- 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000044949 human TNFSF10 Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
Definitions
- the invention relates to the field of genetic engineering, in particular to an albumin-binding tumor necrosis factor-related apoptosis inducing ligand variant, a preparation method thereof and use thereof.
- TNF related apoptosis-inducing ligand is a protein with high selectivity to kill tumor cells. It transmits death signals through the death receptors DR4 and DR5 on the surface of tumor cells, and induces tumor cell apoptosis.
- the death receptors DR4 and DR5 are highly expressed on the surface of tumor cells and are lowly expressed on the surface of normal cells.
- the normal cell surface also highly expresses TRAIL decoy receptors DcR1 and DcR2.
- TRAIL binds to decoy receptors but does not transmit death signals. Therefore, TRAIL is highly toxic or low-toxic to most normal cells while killing tumor cells efficiently.
- hTRAIL human TRAIL
- hTRAIL human TRAIL
- results showed that hTRAIL has good safety and many tumor patients respond to the treatment of hTRAIL.
- hTRAIL has a small molecular weight (about 20 KD per monomer) and is easily cleared by the kidneys in the body, and its half-life in plasma is less than 30 minutes (Xiang H, et al. Drug metabolism and disposition, 2004, 32(11): 1230-1238.).
- the "slow half-life" characteristic greatly impairs the in vivo anti-tumor effect of hTRAIL. Therefore, prolonging the half-life of hTRAIL and increasing its anti-tumor effect has become a new research hotspot.
- Serum albumin as an antitumor drug carrier may increase the half-life of the tumor and may increase the drug absorption of the tumor.
- Serum albumin is the most abundant protein in mammalian serum that binds to the FcRn receptor.
- albumin can also be enriched in tumors and sites of inflammation. Therefore, after the drug forms a complex with albumin, it may not only prolong the half-life of the drug, but also enrich the tumor site, thereby enhancing the anti-tumor effect (Kratz F. Journal of Controlled Release, 2014).
- Methods for preparing hTRAIL-albumin complexes include: 1) direct coupling of hTRAIL to serum albumin; 2) recombinant expression of hTRAIL and albumin encoding gene (Müller N, et al. Biochemical and Biophysical Research Communications, 2010) , 396(4): 793-799).
- the direct coupling method consumes a large amount of albumin, and the recombinant expression of TRAIL and albumin gene is limited.
- the introduction of exogenous serum albumin increases the risk of serious infection.
- the present invention provides an albumin-binding tumor necrosis factor-related apoptosis inducing ligand variant, a preparation method thereof and use thereof.
- the albumin-binding tumor necrosis factor-related apoptosis-inducing ligand variant of the invention is a fusion protein of a tumor necrosis factor-related apoptosis-inducing ligand and an albumin binding domain, and the albumin binding domain is linked to the tumor necrosis factor via a linker The N-terminus of the related apoptosis-inducing ligand.
- amino acid sequence of the tumor necrosis factor-related apoptosis inducing ligand is as shown in SEQ ID NO: 2 or 4.
- amino acid sequence of the albumin binding domain is as shown in SEQ ID NO: 6.
- albumin binding domain is encoded by the nucleotide sequence set forth in SEQ ID NO: 5.
- the linker consists of 2-20 amino acids.
- the linker is a (G4S) 3 linker, the amino acid sequence of which is set forth in SEQ ID NO: 8.
- albumin-binding tumor necrosis factor-related apoptosis inducing ligand variant is encoded by the nucleotide sequence set forth in SEQ ID NO: 9 or 11. Its amino acid sequence is shown as SEQ ID NO: 10 or 12.
- the present invention also provides a nucleotide sequence comprising a coding sequence of a tumor necrosis factor-related apoptosis inducing ligand and a coding sequence of an albumin binding domain, which are linked by a coding sequence of a linker.
- the coding sequence of the tumor necrosis factor-related apoptosis inducing ligand is as shown in SEQ ID NO: 1 or 3.
- albumin binding domain coding sequence is as shown in SEQ ID NO: 5.
- linker is a (G4S) 3 linker, and the nucleotide sequence thereof is shown in SEQ ID NO: 7.
- nucleotide sequence is as shown in SEQ ID NO: 9 or 11.
- the present invention also provides a recombinant vector or recombinant strain of the aforementioned nucleotide sequence.
- the present invention also provides a method for preparing the aforementioned albumin-binding tumor necrosis factor-related apoptosis-inducing ligand variant, which is prepared by genetic engineering using the aforementioned nucleotide sequence as a target fragment.
- the present invention also provides the use of the aforementioned albumin-binding tumor necrosis factor-related apoptosis inducing ligand variant in the preparation of a medicament for treating a cell proliferative disorder.
- the drug for treating a cell proliferative disease is a drug for treating a tumor or an autoimmune disease.
- the present invention also provides an antitumor drug which is prepared by using the aforementioned albumin-binding tumor necrosis factor-related apoptosis-inducing ligand variant as an active ingredient, together with a pharmaceutically acceptable adjuvant.
- the method utilizes the method of adding albumin binding domain to make TRAIL enter the body and use endogenous albumin to prolong the half-life and enhance the anti-tumor effect, and the cost is low, and there is no risk of infection.
- albumin binding domain itself may affect the activity of the target protein.
- the modified target protein may also affect its activity after binding to albumin, and the structure of the protein is complex, and the interaction between protein and protein is also It is unclear, therefore, which albumin binding domain is selected, the fusion protein which is obtained by extending the half-life of the target protein and having excellent pharmacodynamic activity is uncertain, and it is highly probable that an inactive fusion protein is obtained.
- the present inventors screened an albumin binding domain SA21 in the early stage, and did not significantly prolong the half-life of hTRAIL after ligation with hTRAIL; in addition, the albumin binding domain ABD screened by the present invention was ligated to the C-terminus of hTRAIL, not only Significantly prolonged half-life also reduced the in vivo anti-tumor activity of hTRAIL.
- the present invention obtains a specific albumin binding domain and optimizes its nucleotide sequence, and at the same time, the fusion protein prepared by fusion with TRAIL under a specific linkage mode has a long half-life and excellent antitumor activity, and has achieved unexpected results. Less technical effects.
- the invention prepares pure albumin-bound tumor necrosis factor by genetic engineering method
- Sub-related apoptosis-inducing ligand variants ABD-hTRAIL and ABD-mmTRAIL, compared with hTRAIL and mmTRAIL, their half-life is significantly prolonged, and the anti-tumor activity in vivo is also significantly enhanced, and the pharmacodynamic and pharmacokinetic properties are excellent.
- the clinical application prospects are good.
- FIG. 1 ABD-hTRAIL purified SDS-PAGE gel electrophoresis.
- M protein molecular weight standard
- 1 hTRAIL
- 2 ABD-hTRAIL
- FIG. 1 ABD-mmTRAIL purified SDS-PAGE gel electrophoresis.
- M protein molecular weight standard; 1: ABD-mmTRAIL; 2: mmTRAIL
- FIG. 3 ABD-hTRAIL and hTRAIL are compared to albumin binding ability.
- Figure 4 is a comparison of the binding ability of ABD-mmTRAIL and mmTRAIL to albumin.
- Figure 9 ABD-hTRAIL and hTRAIL tumor uptake and tissue distribution comparison.
- 1 heart, 2: liver, 3: spleen, 4: lung, 5: kidney, 6: small intestine, 7: colon, 8: muscle, 9: brain, 10: tumor
- Figure 10 ABD-mmTRAIL and mmTRAIL tumor uptake and tissue distribution comparison.
- 1 heart, 2: liver, 3: spleen, 4: lung, 5: kidney, 6: small intestine, 7: colon, 8: brain, 9: muscle, 10: tumor
- FIG. 11 Comparison of anti-tumor effects of ABD-hTRAIL and hTRAIL in vivo (arrow indicates administration time).
- FIG. 12 Comparison of in vivo antitumor effects of ABD-mmTRAIL and mmTRAIL (arrows indicate administration time).
- albumin-binding domain was ligated to hTRAIL or mmTRAIL to prepare albumin-bound TRAIL variants, ABD-hTRAIL and ABD-mmTRAIL.
- hTRAIL and mmTRAIL are fragments of human and monkey full-length TRAIL 114-281 amino acids.
- the ABD was ligated to the N-terminus of hTRAIL or mmTRAIL via (G4S)3, and the resulting fusion proteins were named ABD-hTRAIL and ABD-mmTRAIL, respectively. Fusion protein for cloning BamHI and NotI restriction sites were added to both ends of the coding gene. The gene was commissioned by Nanjing Jinsirui Company for synthesis.
- the DNA fragment was recovered by agarose gel, and then ligated with the pQE30 vector which was also digested and recovered by gel, and the ligated product was transformed into TOP10. Positive monoclonal strains were initially identified by ampicillin screening (100 ⁇ g/ml) and double restriction enzyme digestion, and positive clones were further verified by DNA sequence analysis.
- the plasmid containing the ABD-hTRAIL or ABD-mmTRAIL coding gene was designated as pQE30-ABD-hTRAIL or pQE30-ABD-mmTRAIL, respectively.
- Table 1 The present invention relates to amino acid and nucleic acid sequences
- the expression plasmid was extracted, the expression strain M15 was transformed, and a positive clone strain was obtained by screening with LB plate medium containing ampicillin (100 ⁇ g/ml) and kanamycin (30 ⁇ g/ml).
- the positive clone strain was inoculated into LB liquid medium containing the same antibiotic, and cultured at 37 ° C until the bacterial solution A 600 reached 0.5 to 1, and 0.05-1 mM isopropylthiogalactoside (IPTG) was added to induce expression. After 4 hours, the cells were collected by centrifugation. The obtained cells were resuspended in phosphate buffer (50 m M, pH 8.0).
- Ni-NTA Super Flow gel was added to the supernatant and slowly shaken at 4 ° C for 3 h. The gel was packed, the heteroprotein was washed with 40 mM imidazole, and eluted with 300 mM imidazole to obtain the protein of interest.
- the purified protein was endotoxin removed using a de-endotoxin kit (Nanjing Kingsray).
- the molecular weights of hTRAIL and mmTRAIL were about 20 KD, and the albumin-bound TRAIL variants formed by fusion of ABD, that is, ABD-hTRAIL and ABD-mmTRAIL had molecular weights of about 25 KD.
- the experimental results show that the albumin-binding tumor necrosis factor-related apoptosis-inducing ligand variants ABD-hTRAIL and ABD-mmTRAIL were prepared by the present invention.
- ABD-hTRAIL or ABD-mmTRAIL and human serum albumin (HSA) were diluted to the same level with phosphate buffer (10 mM Na 2 HPO 4 , 2.68 mM KCl, 2 mM KH 2 PO 4 ) containing 500 mM NaCl. The molar concentration is then mixed in equal volumes. After 10 to 30 min of binding at room temperature, the mixture sample was analyzed on a gel filtration column Superdex 75 (GE Healthcare). hTRAIL and mmTRAIL were used as controls for the fusion proteins ABD-hTRAIL and ABD-mmTRAIL, respectively.
- HSA was dissolved to 20 mg/ml with phosphate buffer PBS (137 mM NaCl, 10 mM Na 2 HPO 4 , 2.68 mM KCl, 2 mM KH 2 PO 4 ). HSA (100 ⁇ l/well) was added to the plate and coated overnight at 4 °C. The plate was washed twice with PBS (200 ⁇ l/well), and 100 ⁇ l of different concentrations of fusion protein were added. After incubating for 2 h at 37 ° C, the plate was washed 4 times with PBST (PBS + 0.075% Tween 20), and then incubated with mouse anti-TRAIL antibody for 1 h.
- PBST PBS + 0.075% Tween 20
- hTRAIL and mmTRAIL were incubated with HSA and detected with an anti-TRAIL antibody, and the color reaction did not change with an increase in protein concentration.
- concentration of ABD-hTRAIL and ABD-mmTRAIL increased, the A 450 nm absorption value also increased accordingly. This result indicates that hTRAIL and mmTRAIL hardly bind to HSA.
- ABD-hTRAIL and ABD-mmTRAIL can be combined with HSA.
- the experimental results indicate that the albumin-binding tumor necrosis factor-related apoptosis-inducing ligand variants prepared by the present invention: ABD-hTRAIL and ABD-mmTRAIL all have albumin binding ability.
- Colon cancer Colo205 cells were seeded in RPMI 1640 and cultured at 37 ° C, 5% CO 2 .
- ABD-hTRAIL and ABD-mmTRAIL were mixed with has 1:1, respectively, and added to the cells (20000 cells/well) after 30-60 min at room temperature. After overnight action, 10 ul of CCK8 was added to the wells to determine cell viability.
- ABD-hTRAIL and ABD-mmTRAIL bind to proteins and have a killing effect on tumor cells.
- the experimental results show that the albumin-binding tumor necrosis factor-related apoptosis-inducing ligand variants prepared by the present invention: ABD-hTRAIL and ABD-mmTRAIL have tumor cell killing activity after binding to albumin, and can be used for anti-tumor in vivo. .
- mice were divided into two groups. One group was injected with hTRAIL or mmTRAIL protein at a tail vein of 10 mg/kg. The other group injected the same amount of ABD-hTRAIL or ABD-mmTRAIL. Blood was taken at different time points after injection, heparin was anticoagulated, and mouse plasma was obtained by centrifugation. After the mouse plasma was diluted 25, 50, 100 and 250 times with RMPI1640 medium, the killing activity was measured using Colo205 cells. The rate of protein metabolism in vivo is monitored by changes in residual protein activity in plasma.
- albumin-binding tumor necrosis factor-related apoptosis-inducing ligand variants prepared by the present invention have slow metabolism and long half-life in vivo compared with hTRAIL and mmTRAIL.
- the retention time in the body is long.
- ABD-hTRAIL and hTRAIL were labeled with CF750 fluorescent dye, respectively.
- 5 ⁇ 10 5 Colo205 cells 100 ⁇ l were inoculated subcutaneously into the right hind limb of nude mice.
- 50 ug of CF750-labeled protein was administered by tail vein injection, and then at 2, 4, 8 , 24h in vivo imaging scan to observe the protein intake by the tumor.
- the mice were sacrificed and the organs and tissues were removed for scanning to examine the tissue distribution of the protein.
- hTRAIL and ABD-hTRAIL were detected in the tumor 2 hours after intravenous injection.
- the amount of hTRAIL uptake by the tumor increased compared with 2h.
- the amount of hTRAIL in the tumor was significantly reduced.
- ABD-hTRAIL uptake reached the peak during 4-8h, but the amount of protein did not decrease significantly after 24h.
- the mouse tissue was removed and found to have more ABD-hTRAIL content than hTRAIL.
- the two proteins are mainly distributed in the liver and kidney of the metabolic organs. Consistent with in vivo imaging observations, tissue-organ scans also demonstrated that ABD-hTRAIL is more readily enriched in tumor tissue than hTRAIL.
- ABD-mmTRAIL and mmTRAIL show the same pattern by tumor absorption and tissue distribution. As a result, as shown in FIG. 10, both in vivo imaging and tissue distribution showed that ABD-mmTRAIL was more easily enriched in tumor tissues than mmTRAIL.
- albumin-binding tumor necrosis factor-related apoptosis-inducing ligand variants ABD-hTRAIL and ABD-mmTRAIL prepared by the present invention were more targeted than hTRAIL and mmTRAIL.
- 5 ⁇ 10 5 Colo205 cells (100 ⁇ l) were inoculated subcutaneously into the right hind limb of nude mice and randomly divided into groups. At a certain time after inoculation, 5 mg/kg protein was administered by tail vein injection, and the control group was given the same volume of PBS. Tumor size was recorded daily and mice were sacrificed at 24 days and tumors were taken.
- the tumor growth trend of the ABD-hTRAIL group was significantly delayed compared with the hTRAIL group.
- the sizes of the PBS control group, hTRAIL group and ABD-hTRAIL group were: 674.3 ⁇ 194.1 mm 3 , 546.1 ⁇ 265.1 mm 3 and 65.6 + 41.7 mm 3 (Fig. 11A). Tumor size observations were consistent with growth curve results ( Figure 11B).
- the tumor weights of the hTRAIL group and the ABD-hTRAIL group were 0.367 ⁇ 0.06 g, 0.32 ⁇ 0.09 g, and 0.016 ⁇ 0.02 g, respectively.
- Figure 12 shows that ABD-mmTRAIL is similar to ABD-hTRAIL treatment.
- the tumor growth was significantly slower than that of the mmTRAIL treatment group in the ABD-mmTRAIL group.
- the tumor sizes of the PBS control, mmTRAIL group and ABD-mmTRAIL group were 925.7 ⁇ 222.7 mm 3 , 642.4 ⁇ 194.5 mm 3 and 152.3 ⁇ 44.7 mm 3 , respectively (Fig. 12A).
- Tumor size was consistent with tumor growth curve results (Figure 12B).
- the average weight of the tumor in the PBS control group, mmTRAIL group and ABD-mmTRAIL group was 0.539 ⁇ 0.069 g, 0.341 ⁇ 0.089 g, and 0.088+0.028 g, respectively.
- albumin-binding tumor necrosis factor-related apoptosis-inducing ligand variants prepared by the present invention ABD-hTRAIL and ABD-mmTRAIL have stronger in vivo antitumor activity than hTRAIL and mmTRAIL.
- the invention provides a pure albumin-binding tumor necrosis factor-related apoptosis-inducing ligand variant: ABD-hTRAIL and ABD-mmTRAIL by genetic engineering, and their half-life is significantly prolonged compared with hTRAIL and mmTRAIL.
- ABD-hTRAIL and ABD-mmTRAIL by genetic engineering, and their half-life is significantly prolonged compared with hTRAIL and mmTRAIL.
- the anti-tumor activity in the body is also obviously enhanced, the pharmacodynamics and pharmacokinetic performance are excellent, and the clinical application prospect is good.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne un variant de ligand induisant l'apoptose apparenté au facteur de nécrose des tumeurs conjugué à l'albumine, et le variant est une protéine de fusion ligand induisant l'apoptose apparenté au facteur de nécrose des tumeurs et domaine de liaison de l'albumine. L'invention concerne également une séquence nucléotidique codant pour le variant, un vecteur recombinant et une bactérie recombinante comprenant la séquence nucléotidique, et un procédé de préparation dudit variant et une utilisation du variant.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2015/073483 WO2016138610A1 (fr) | 2015-03-02 | 2015-03-02 | Variant de ligand induisant l'apoptose apparenté au facteur de nécrose des tumeurs conjugué à l'albumine, procédé de préparation associé et utilisation associée |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2015/073483 WO2016138610A1 (fr) | 2015-03-02 | 2015-03-02 | Variant de ligand induisant l'apoptose apparenté au facteur de nécrose des tumeurs conjugué à l'albumine, procédé de préparation associé et utilisation associée |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016138610A1 true WO2016138610A1 (fr) | 2016-09-09 |
Family
ID=56849129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/073483 WO2016138610A1 (fr) | 2015-03-02 | 2015-03-02 | Variant de ligand induisant l'apoptose apparenté au facteur de nécrose des tumeurs conjugué à l'albumine, procédé de préparation associé et utilisation associée |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016138610A1 (fr) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012130471A1 (fr) * | 2011-04-01 | 2012-10-04 | Universität Stuttgart | Polypeptides recombinés membres de la famille des ligands tnf ayant un domaine de liaison à l'anticorps et leurs utilisations |
-
2015
- 2015-03-02 WO PCT/CN2015/073483 patent/WO2016138610A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012130471A1 (fr) * | 2011-04-01 | 2012-10-04 | Universität Stuttgart | Polypeptides recombinés membres de la famille des ligands tnf ayant un domaine de liaison à l'anticorps et leurs utilisations |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110835371A (zh) | 抗ccr8单克隆抗体及其应用 | |
US20210100916A1 (en) | Preparation and use of mitochondrion-targeting self-assembled protein nanoparticle | |
US20170260246A1 (en) | Carcinoma homing peptide (chp), its analogs, and methods of using | |
WO2013003987A1 (fr) | Variant de ligand d'apoptose associée à un facteur de nécrose tumorale ciblé vers une tumeur, et son utilisation | |
CN106632682A (zh) | 融合蛋白ifn-elp及其应用 | |
CN102250245A (zh) | 抗b细胞淋巴瘤的双特异性抗体及其用途 | |
BR112013013548B1 (pt) | Proteína de fusão anticancerígena | |
JP2014527072A (ja) | ウイルスタンパク質の集合を制御するための方法および組成物 | |
WO2011011973A1 (fr) | Protéine de fusion d'un fragment fab d'anticorps anti-cd20 et de lidamycine, son procédé de préparation et son utilisation | |
JP2001521733A (ja) | ヒト上皮増殖因子とヒトアンギオゲニンの融合タンパク質およびその製造方法 | |
EP4261230A1 (fr) | Protéine de fusion de domaine de liaison à l'albumine sérique-collagène humaine recombinante pour matrice de ciblage spécifique d'une tumeur et son utilisation | |
WO2015055026A1 (fr) | Protéine de fusion associant la protéine immunorégulatrice de ganoderma lucidum et la sérumalbumine humaine, son procédé de production et ses utilisations | |
WO2021083077A1 (fr) | Médicament et sa bibliothèque d'extension de demi-vie, procédé de préparation correspondant et utilisation associée | |
CN111777667B (zh) | 小肽及其在制备免疫调节药物中的应用 | |
WO2008145013A1 (fr) | Protéine hybride comprenant un peptide de ciblage de cd13 et lidamycine | |
CN109400711B (zh) | 一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途 | |
CN105985447B (zh) | 一种白蛋白结合型肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途 | |
US11566045B2 (en) | Tumor targeting polypeptide and method of use thereof | |
Chen et al. | A single nucleotide mutation drastically increases the expression of tumor-homing NGR-TNFα in the E. coli M15-pQE30 system by improving gene transcription | |
WO2016138610A1 (fr) | Variant de ligand induisant l'apoptose apparenté au facteur de nécrose des tumeurs conjugué à l'albumine, procédé de préparation associé et utilisation associée | |
US10428132B2 (en) | Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof | |
CN101144081B (zh) | 核苷酸分子trail及其在制备治疗肿瘤药物中的应用 | |
CN101880327A (zh) | 蝎镇痛抗肿瘤缬精甘肽融合体及其获得方法 | |
CN102260352B (zh) | 靶向性白细胞介素融合蛋白及其制备方法与应用 | |
CN106674352B (zh) | 抗肿瘤蛋白内皮抑素的衍生物及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15883667 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15883667 Country of ref document: EP Kind code of ref document: A1 |